Long-term ozone exposure associated cause-specific mortality risks with adjusted metrics by cohort studies: A systematic review and meta-analysis
Authors: Sun Haitong Zhe , Yu Pei , Lan Changxin , Wan Michelle , Hickman Sebastian , Murulitharan Jayaprakash , Shen Huizhong , Yuan Le , Guo Yuming , Archibald Alexander T. 
Published: December 2021

BACKGROUND

Long-term ozone (O3) exposure could lead to a series of non-communicable diseases and increase the mortality risks. However, cohort-based studies were still rather rare, and inconsistent exposure metrics might impair the credibility of epidemiological evidence synthetisation. To provide more accurate meta-estimation, this review updated the systematic review with inclusion of recent studies and summarised the quantitative associations between O3 exposure and cause-specific mortality risks based on unified exposure metrics.

METHODS

Research articles reporting relative risks between incremental long-term O3 exposure and causes of mortality covering all-cause, cardiovascular diseases, respiratory diseases, chronic obstructive pulmonary disease, pneumonia, ischaemic heart diseases, ischaemic stroke, congestive heart failure, cerebrovascular diseases, and lung cancer, estimated from cohort studies were identified through systematic searches in MEDLINE, Embase and Web of Science. Cross-metric conversion factors were estimated linearly by decadal of observations during 1990-2019. The Hunter-Schmidt random effect estimator was applied to pool the relative risks.

RESULTS

A total of 25 studies involving 226,453,067 participants (14 unique cohorts covering 99,855,611 participants) were included in the systematic review. After linearly adjusting the inconsistent O3 exposure metrics into congruity, the pooled relative risks (RR) associated with every 10 nmol mol-1 (ppbV) incremental O3 exposure, by mean of warm-season daily maximum 8-hour average metric, was: 1.014 with 95% confidence interval (CI) ranging 1.009–1.019 for all-cause mortality; 1.025 (95% CI: 1.010–1.040) for respiratory mortality; 1.056 (95% CI: 1.029–1.084) for COPD mortality; 1.019 (95% CI: 1.004–1.035) for cardiovascular mortality; and 1.096 (95% CI: 1.065–1.129) for congestive heart failure mortality. Insignificant mortality risk associations were found for ischaemic heart disease, cerebrovascular diseases and lung cancer.

DISCUSSION

This review covered up-to-date studies, expanded the O3-exposure associated mortality causes into wider range of categories, and firstly highlighted the issue of inconsistency in O3 exposure metrics. Non-intercept linear regression-based cross-metric RR conversion was another innovation, but limitation lay in the observation reliance, indicating further calibration with more credible observations available. Large uncertainties in the multi-study pooled RRs would inspire more future studies to corroborate or contradict the results from this review.

CONCLUSION

Adjustment for exposure metrics laid more solid foundation for multi-study meta-analysis, and wider coverage of surface O3 observations are anticipated to strengthen the cross-metric conversion in the future. Ever-growing numbers of epidemiological studies supported unneglectable cardiopulmonary hazards and all-cause mortality risks from long-term O3 exposure. However, evidences on long-term O3 exposure associated health effects were still scarce, and hence more relevant studies are encouraged to cover more population with regional diversity.

REGISTRATION

The review was registered in PROSPERO (CRD42021270637).

FUNDING

This study is mainly funded by UK Natural Environment Research Council, UK National Centre for Atmospheric Science, Australian Research Council and Australian National Health and Medical Research Council.

Highlights

Updated evidence for O3-mortality associations from 25 cohorts has been provided.

Adjusting various O3exposure metrics can provide more accurate risk estimations.

Long-term O3-exposure was associated with increased mortality from all-causes, respiratory disease, COPD, cardiovascular disease and congestive heart failure.